CELESTIAL

Members of the Exchange are hereby informed about the delisting of equity shares of Celestial Biolabs Limited w.e.f. October 17, 2024 in terms of Rule 21(2) (b) of the Securities Contracts (Regulations) Rules 1957.

Celestial Biolabs Limited has informed the Exchange regarding Appointment of Mr Dattatreya Rao as Executive Director of the company w.e.f. April 22, 2024.

This is to inform you that the Board Meeting of the company which was scheduled on 30.05.2024 stand cancelled due to non-finalization of accounts

Celestial Biolabs Limited has informed the Exchange regarding voting results of Annual General Meeting held on May 23, 2024

Celestial Biolabs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on May 23, 2024

Celestial Biolabs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on May 23, 2024

Celestial Biolabs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.

The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 30-Sep-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.

The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 30-Jun-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.

Celestial Biolabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Celestial Biolabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Celestial Biolabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Celestial Biolabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Celestial Biolabs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 21-May-2024 to 23-May-2024 for the purpose of Meeting.

Celestial Biolabs Limited has informed the Exchange regarding Board meeting held on April 22, 2024.

Celestial Biolabs Limited has informed the Exchange regarding Resignation of Mr Amarachinta Padmanabha Rao as Non- Executive Independent Director of the company w.e.f. April 22, 2024.

Celestial Biolabs Limited has informed the Exchange regarding Appointment of Mr Dattatreya Rao as Executive Director of the company w.e.f. April 22, 2024.

Celestial Biolabs Limited has informed the Exchange regarding Change in Auditors of the company.

Celestial Biolabs Limited has informed the Exchange regarding Appointment of Mr Dattatreya Rao as Chief Executive Officer of the company w.e.f. April 22, 2024.

Celestial Biolabs Limited has informed the Exchange regarding Demise of Mr Devarakonda Chidvilasa Sastri, Non- Executive Independent Director of the company on April 22, 2024.

CELESTIAL BIOLABS LIMITED has informed the Exchange about Resignation of Independent director.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2023.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2023.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2023.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2023.

This is to inform you that the Board Meeting of the company which was scheduled to be held on 06.03.2024 stand cancelled due to non-availability of Independent directors.

Celestial Biolabs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Celestial Biolabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

The Exchange had sought clarification from Celestial Biolabs Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted -2. Consolidated Financial Results not submitted The response of the Company is enclosed.

The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted -2. Consolidated Financial Results not submitted The response of the Company is awaited.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2022.

Celestial Biolabs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Celestial Biolabs Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended 31st December, 2022'.

��The Exchange had sought clarification from Celestial Biolabs Limited with respect to Financial Results dated 14-Nov-2022 for the period Sep, 2022On the basis of aforesaid disclosure, the Listed entity was required to clarify the following:1.Standalone: Segment Reporting - Not found. The response of the company is attached.

The Exchange had sought clarification from Celestial Biolabs Limited with respect to announcement dated 03-09-2022 regarding Appointment.On the basis of aforesaid disclosure, the Listed entity was required to clarify the following:Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), Auditor and Compliance Officer:1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authorityThe response of the company is attached.

The Exchange has sought clarification from Celestial Biolabs Limited with respect to Financial Results dated 14-Nov-2022 for the period Sep, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:1.Standalone: Segment Reporting - Not foundThe response of the company is awaited

Celestial Biolabs Limited has informed the Exchange about related party transaction for the period ended September 2022

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended June and September 2022

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended June and September 2022

Celestial Biolabs Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September, 2022

Celestial Biolabs Limited has informed the Exchange about Scrutinizer report (FY 2021-22) of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange about Voting results (FY 2021-22) of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange about Proceedings (FY 2021-22) of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange about Scrutinizer report (FY 2020-21) of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange about Voting results (FY 2020-21) of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange about Proceedings of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange about Scrutinizer report of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange about Voting results of Annual General Meeting held on 30-Sep-2022